Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children
Conditions: Diphtheria; Tetanus Interventions: Biological: BR-TD-1001; Biological: Td-pur inj Sponsor: Boryung Biopharma Co., Ltd. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials